1160 participants
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-13
- Start Date:
- 2024-11-18
- Completion:
- 2030-07-01
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG
No Results Yet